Circulating colony stimulating factor-1 and breast cancer risk.

Circulating colony stimulating factor-1 and breast cancer risk. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Circulating colony stimulating factor-1 and breast cancer risk. Abstract Text:

Rulla M Tamimi,Joan S Brugge,Matthew L Freedman,Alexander Miron,J Dirk Iglehart,Graham A Colditz,Susan E Hankinson,Rulla M Tamimi,Joan S Brugge,Matthew L Freedman,Alexander Miron,J Dirk Iglehart,Graham A Colditz,Susan E Hankinson,

Colony stimulating factor-1 (CSF1) and its receptor (CSF1-R) are important in mammary gland development and have been implicated in breast carcinogenesis. In a nested case-control study in the Nurses' Heath Study of 726 breast cancer cases diagnosed between June 1, 1992, and June 1, 1998, and 734 matched controls, we prospectively evaluated whether circulating levels of CSF1 (assessed in 1989-1990) are associated with breast cancer risk. The association varied by menopausal status (P(heterogeneity) = 0.009). CSF1 levels in the highest quartile (versus lowest) were associated with an 85% reduced risk of premenopausal breast cancer [relative risk (RR), 0.15; 95% confidence interval (95% CI), 0.03-0.85; P(trend) = 0.02]. In contrast, CSF1 levels in the highest quartile conferred a 33% increased risk of postmenopausal breast cancer (RR, 1.33; 95% CI, 0.96-1.86; P(trend) = 0.11), with greatest risk for invasive (RR, 1.45; 95% CI, 1.02-2.07; P(trend) = 0.06) and ER+/PR+ tumors (RR, 1.72; 95% CI, 1.11-2.66; P(trend) = 0.04). Thus, the association of circulating CSF1 levels and breast cancer varies by menopausal status.

Circulating colony stimulating factor-1 and breast cancer risk. Publishing Authors By Initials

RM Tamimi,JS Brugge,ML Freedman,A Miron,JD Iglehart,GA Colditz,SE Hankinson,RM Tamimi,JS Brugge,ML Freedman,A Miron,JD Iglehart,GA Colditz,SE Hankinson,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Circulating colony stimulating factor-1 and breast cancer risk. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Cancer research

VOLUME: 68

Page Numbers: 18-21

Journal Abbreviation: Cancer Res.

ISSN: 1538-7445

DAY: 1

MONTH: Jan

YEAR: 2008

Circulating colony stimulating factor-1 and breast cancer risk. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 2984705

Circulating colony stimulating factor-1 and breast cancer risk. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Circulating colony stimulating factor-1 and breast cancer risk. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Circulating colony stimulating factor-1 and breast cancer risk.

AFFILIATION: Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. rulla.tamimi@channing.harvard.edu

Country: United States

AGENCY: United States NCI

GRANT: CA089393

ACRONYM: CA

MEDLINETA: Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Circulating colony stimulating factor-1 and breast cancer risk Related Publications

• A novel promoter element containing multiple overlapping xenobiotic and hypoxia response elements mediates induction of cytochrome P4502S1 by both dioxin and hypoxia.
• A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer.
• A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer.
• A prospective study of postmenopausal hormone use and ovarian cancer risk.
• Aspirin, NSAID, and Acetaminophen Use and the Risk of Endometrial Cancer.
• Association of activity and chronic disease risk factors: utility and limitations of objectively measured physical activity data.
• Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk.
• Birthweight and body size throughout life in relation to sex hormones and prolactin concentrations in premenopausal women.
• Body shape throughout life and correlations with IGFs and GH.
• Breastfeeding and risk of ovarian cancer in two prospective cohorts.
• Caffeine, alcohol, smoking, and the risk of incident epithelial ovarian cancer.
• Circulating colony stimulating factor-1 and breast cancer risk.
• Circulating insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women.
• Circulating levels of sex steroids and prolactin in premenopausal women and risk of breast cancer.
• Dietary patterns, the Alternate Healthy Eating Index and plasma sex hormone concentrations in postmenopausal women.
• Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women.
• Identification of novel dioxin-responsive genes by representational difference analysis.
• Identifying target genes of the aryl hydrocarbon receptor nuclear translocator (Arnt) using DNA microarray analysis.
• Insulin-like growth factors and ovarian cancer risk: a nested case-control study in three cohorts.
• Menopausal and reproductive factors and risk of age-related macular degeneration.
• Physical activity and inactivity in relation to sex hormone, prolactin, and insulin-like growth factor concentrations in premenopausal women - exercise and premenopausal hormones.
• Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of incident ovarian cancer.
• Plasma adiponectin concentrations and risk of incident breast cancer.
• Plasma androgen concentrations and risk of incident ovarian cancer.
• Prolactin and breast cancer risk.
• Relationship of plasma adiponectin with sex hormone and insulin-like growth factor levels.
• Reproducibility of proteomic profiles over 3 years in postmenopausal women not taking postmenopausal hormones.
• The role of the aryl hydrocarbon receptor nuclear translocator protein in aryl hydrocarbon receptor action.
• Use of biomarkers in epidemiologic studies: minimizing the influence of measurement error in the study design and analysis.
• Why does ARNT2 behave differently from ARNT?